# Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

> **NCT06814496** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Arizona** · enrollment: 30 (estimated)

## Conditions studied

- Melanoma
- Medullary Thyroid Cancer
- Sinonasal Undifferentiated Carcinoma
- Esthesioneuroblastoma
- Bladder Cancer
- Testicular Cancer
- Glioblastoma Multiforme
- Cervical Cancer
- Large Cell Neuroendocrine Carcinoma of the Lung
- Non Small Cell Lung Cancer
- Merkel Cell Carcinoma

## Interventions

- **DRUG:** Tarlatamab
- **RADIATION:** Concurrent Radiation Therapy
- **RADIATION:** Sequential Radiation therapy

## Key facts

- **NCT ID:** NCT06814496
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-08
- **Primary completion:** 2030-05
- **Final completion:** 2030-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06814496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06814496, "Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06814496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*